Mainz Biomed N.V. (BST: 4TO)
Germany
· Delayed Price · Currency is EUR 0.209
-0.024 (-10.13%)
At close: Nov 18, 2024
Mainz Biomed Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 0.92 | 0.9 | 0.53 | 0.58 | 0.49 | 0.28 |
| Revenue Growth (YoY) | 16.23% | 69.00% | -8.22% | 16.98% | 75.40% | - |
| Cost of Revenue | 0.38 | 0.39 | 0.35 | 0.4 | 0.37 | 0.34 |
| Gross Profit | 0.54 | 0.51 | 0.18 | 0.18 | 0.12 | -0.06 |
| Selling, General & Admin | 15.23 | 17.56 | 21.61 | 9.42 | 0.48 | 0.61 |
| Research & Development | 7.35 | 9.59 | 5.02 | 0.48 | 0.31 | 0.25 |
| Operating Expenses | 22.58 | 27.15 | 26.63 | 9.9 | 0.8 | 0.86 |
| Operating Income | -22.04 | -26.64 | -26.44 | -9.72 | -0.67 | -0.92 |
| Interest Expense | -1.13 | -0.56 | -0.29 | -0.34 | -0.27 | -0.2 |
| Other Non Operating Income (Expenses) | 0.53 | 0.2 | 0.35 | 0.39 | 0.33 | 0.17 |
| EBT Excluding Unusual Items | -22.64 | -27.01 | -26.39 | -9.67 | -0.62 | -0.96 |
| Merger & Restructuring Charges | - | - | - | -2.02 | 0.03 | - |
| Other Unusual Items | 0.14 | 0.71 | - | - | - | - |
| Pretax Income | -22.51 | -26.3 | -26.39 | -11.69 | -0.59 | -0.96 |
| Net Income | -22.51 | -26.3 | -26.39 | -11.69 | -0.59 | -0.96 |
| Net Income to Common | -22.51 | -26.3 | -26.39 | -11.69 | -0.59 | -0.96 |
| Shares Outstanding (Basic) | 20 | 16 | 14 | 7 | 6 | 6 |
| Shares Outstanding (Diluted) | 20 | 16 | 14 | 7 | 6 | 6 |
| Shares Change (YoY) | 36.64% | 14.73% | 96.33% | 28.60% | - | - |
| EPS (Basic) | -1.12 | -1.62 | -1.86 | -1.62 | -0.10 | -0.17 |
| EPS (Diluted) | -1.12 | -1.62 | -1.86 | -1.62 | -0.10 | -0.17 |
| Free Cash Flow | -19.6 | -23.14 | -15.43 | -3.24 | -0.48 | -0.42 |
| Free Cash Flow Per Share | -0.98 | -1.42 | -1.09 | -0.45 | -0.09 | -0.07 |
| Gross Margin | 58.98% | 56.91% | 34.38% | 30.77% | 24.94% | -21.77% |
| Operating Margin | -2402.78% | -2975.47% | -4990.60% | -1684.36% | -136.50% | -327.62% |
| Profit Margin | -2453.86% | -2936.50% | -4979.90% | -2024.79% | -118.91% | -340.11% |
| Free Cash Flow Margin | -2136.98% | -2583.83% | -2911.63% | -560.67% | -96.93% | -148.01% |
| EBITDA | -21.59 | -26.07 | -26.28 | -9.65 | -0.61 | -0.87 |
| EBITDA Margin | - | - | - | - | -124.25% | - |
| D&A For EBITDA | 0.45 | 0.57 | 0.16 | 0.07 | 0.06 | 0.05 |
| EBIT | -22.04 | -26.64 | -26.44 | -9.72 | -0.67 | -0.92 |
| EBIT Margin | - | - | - | - | -136.50% | - |
| Advertising Expenses | - | - | - | - | - | 0.02 |
Source: S&P Capital IQ. Standard template. Financial Sources.